Assignee
CELLTAXIS LLC
US·6 granted patents·3 pending applications·9 citations·filing 2019–2024
Top patents by PatentIndex Score
9 records- 0190US11267819B2Diamine derivatives as inhibitors of leukotriene A4 hydrolaseCELLTAXIS LLC·Filed 2020·Granted Mar 8, 2022·2 cites·21 claims
- 0289US10898484B2Method of reducing pulmonary exacerbations in respiratory disease patientsCELLTAXIS LLC·Filed 2019·Granted Jan 26, 2021·5 cites·27 claims
- 0388US11890282B2Method of reducing pulmonary exacerbations in respiratory disease patientsCELLTAXIS LLC·Filed 2021·Granted Feb 6, 2024·2 cites·24 claims
- 0488US2025296935A1Diamine Derivatives as Inhibitors of Leukotriene A4 HydrolaseCELLTAXIS LLC·Filed 2024·Application pending·0 cites
- 0581US12558353B2Method of reducing pulmonary exacerbations in respiratory disease patientsCELLTAXIS LLC·Filed 2023·Granted Feb 24, 2026·0 cites·15 claims
- 0681US12173009B2Diamine derivatives as inhibitors of leukotriene A4 hydrolaseCELLTAXIS LLC·Filed 2022·Granted Dec 24, 2024·0 cites·23 claims
- 0769US10898471B2Methods of inhibiting leukotriene A4 hydrolaseCELLTAXIS LLC·Filed 2019·Granted Jan 26, 2021·0 cites·7 claims
- 0857US2024398793A1Methods of Treating LymphedemaCELLTAXIS LLC·Filed 2024·Application pending·0 cites
- 0954US2022288034A1Method of reducing aberrant immune response or risk of progression in covid-19CELLTAXIS LLC·Filed 2022·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →